- How biomanufacturing can address the dichotomy of small volume precision medicines and high volume blockbuster drugs
- Building flexible global manufacturing networks to meet our industry’s evolving needs
- Leveraging cutting edge innovation to maximize process intensification and augment flexibility
- Creating high performance teams and building and maintaining a culture of quality, reliability and innovation as key differentiator and foundation for continued success
Please note: Q&A appears in this separate video:
—
President & CEO, BI Fremont Inc.
Boehringer Ingelheim Biopharmaceuticals GmbH
Dr. Jens Vogel is President and CEO of Boehringer Ingelheim Fremont Inc., the US arm of Boehringer Ingelheims Biopharmaceuticals Unit. Jens has 20 years of experience in all aspects of biopharmaceutical development and manufacturing, through senior leadership roles in process & technology development, GMP manufacturing and global program leadership in the US, Germany and the UK.
Prior to his current role, Jens was Global Head of CMC Strategy & TechRA, covering CMC development and global regulatory strategy for the entire portfolio of innovative BI biologics, Biosimilars, as well as, all contract development and manufacturing projects.
Before he joined Boehringer Ingelheim, Jens was part of Bayer’s Global Biologics Development Leadership Team in Berkeley.
To date, Jens and his teams contributed to the successful licensure and post launch support of multiple commercial biologics, as well as, more than 60 INDs/IMPDs.
Jens’ interests include reliable supply of biologic therapies to patients, disruptive innovation in technology and business models, and strategic collaborations to maximize value generation for all stakeholders. He is very active in the industry community and was voted as one of the 100 most influential people in drug development and manufacture (The Medicine Maker Power List 2015).
